Statement of Organization, Functions, and Delegations of Authority, 6777 [06-1199]
Download as PDF
<![CDATA[
Federal Register / Vol. 71, No. 27 / Thursday, February 9, 2006 / Notices
A Web
address for the meeting will be available
at: https://www.hhs.gov/healthit.
SUPPLEMENTARY INFORMATION:
Dated: February 1, 2006.
Dana Haza,
Office of Programs and Coordination, Office
of the National Coordinator.
[FR Doc. 06–1180 Filed 2–8–06; 8:45 am]
BILLING CODE 4150–24–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Statement of Organization, Functions,
and Delegations of Authority
Part C (Centers for Disease Control
and Prevention) of the Statement of
Organization, Functions, and
Delegations of Authority of the
Department of Health and Human
Services (45 FR 67772–76, dated
October 14, 1980, and corrected at 45 FR
69296, October 20, 1980, as amended
most recently at 70 FR 72842–72843,
dated December 7, 2005) is amended to
reflect the title change for the Division
of Injury and Disability Outcomes,
National Center for Injury Prevention
and Control, Centers for Disease Control
and Prevention.
Section C–B, Organization and
Functions, is hereby amended as
follows:
Delete in its entirety the title for the
Division of Injury and Disability
Outcomes (CE6) and insert the Division
of Injury Response (CTCE).
Dated: January 27, 2006
William H. Gimson,
Chief Operating Officer, Centers for Disease
Control and Prevention (CDC).
[FR Doc. 06–1199 Filed 2–8–06; 8:45 am]
BILLING CODE 4160–18—M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
cprice-sewell on PROD1PC66 with NOTICES
Advisory Committee on Special
Studies Relating to the Possible LongTerm Health Effects of Phenoxy
Herbicides and Contaminants (Ranch
Hand Advisory Committee); Notice of
Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
VerDate Aug<31>2005
17:24 Feb 08, 2006
Jkt 208001
(FDA). The meeting will be open to the
public.
Name of Committee: Advisory Committee
on Special Studies Relating to the Possible
Long-Term Health Effects of Phenoxy
Herbicides and Contaminants (Ranch Hand
Advisory Committee).
General Function of the Committee: To
advise the Secretary of Health and Human
Services (the Secretary) and the Assistant
Secretary for Health concerning its oversight
of the conduct of the Ranch Hand study by
the U.S. Air Force and provide scientific
oversight of the Department of Veterans
Affairs Army Chemical Corps Vietnam
Veterans Health Study, and other studies in
which the Secretary or the Assistant
Secretary for Health believes involvement by
the committee is desirable.
Date and Time: The meeting will be held
on February 27, 2006, from 8:30 a.m. to 4
p.m.
Location: Food and Drug Administration,
5630 Fishers Lane, rm. 1066, Rockville, MD.
Contact Person: Leonard Schechtman,
National Center for Toxicological Research
(HFT–10), Food and Drug Administration,
5600 Fishers Lane, Rockville, MD 20857,
301–827–6696, or FDA Advisory Committee
Information Line, 1–800–741–8138 (301–
443–0572 in the Washington, DC area), code
3014512560. Please call the Information Line
for up-to-date information on this meeting.
Agenda: The committee will discuss the
following items: (1) Update on the Institute
of Medicine’s Air Force Health Study
Disposition Study and related closure
activities; (2) updates from the Air Force on
the Viability Study, Compliance Study,
Comprehensive Study, Mortality Update,
Technical Reports, and External
Collaborations.
Procedure: Interested persons may present
data, information, or views, orally or in
writing, on issues pending before the
committee. Written submissions may be
made to the contact person by February 17,
2006. Oral presentations from the public will
be scheduled on February 27, 2006, between
approximately 11:30 a.m. and 12:30 p.m.
Time allotted for each presentation may be
limited. Those desiring to make formal oral
presentations should notify the contact
person before February 17, 2006, and submit
a brief statement of the general nature of the
evidence or arguments they wish to present,
the names and addresses of proposed
participants, and an indication of the
approximate time requested to make their
presentation.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee meetings
and will make every effort to accommodate
persons with physical disabilities or special
needs. If you require special accommodations
due to a disability, please contact Leonard
Schechtman at least 7 days in advance of the
meeting.
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
6777
Notice of this meeting is given under the
Federal Advisory Committee Act (5 U.S.C.
app. 2).
Dated: February 2, 2006.
Jason Brodsky,
Acting Associate Commissioner for External
Relations.
[FR Doc. E6–1737 Filed2–8–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2004D–0385]
Guidance for Industry and Food and
Drug Administration Staff; Class II
Special Controls Guidance Document;
Hepatitis A Virus Serological Assays;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of the guidance document
entitled ‘‘Guidance for Industry and
FDA Staff: Class II Special Controls
Guidance Document: Hepatitis A Virus
Serological Assays.’’ The guidance
document describes a means by which
these in vitro diagnostic devices for the
laboratory diagnosis of hepatitis A virus
(HAV) may comply with the
requirement of special controls for class
II devices. Elsewhere in this issue of the
Federal Register, FDA is publishing a
final rule reclassifying these devices
from class III (premarket approval) into
class II (special controls). HAV
serological assays are in vitro diagnostic
devices used to test for specific
antibodies to support the clinical
laboratory diagnosis of HAV.
DATES: Submit written or electronic
comments on this guidance at any time.
General comments on agency guidance
documents are welcome at any time.
ADDRESSES: Submit written requests for
single copies on a 3.5″ diskette of the
guidance document entitled ‘‘Guidance
for Industry and FDA Staff: Class II
Special Controls Guidance Document:
Hepatitis A Virus Serological Assays’’ to
the Division of Small Manufacturers,
International, and Consumer Assistance
(HFZ–220), Center for Devices and
Radiological Health, Food and Drug
Administration, 1350 Piccard Dr.,
Rockville, MD 20850. Send one selfaddressed adhesive label to assist that
office in processing your request, or fax
your request to 301–443–8818. See the
SUPPLEMENTARY INFORMATION section for
E:\FR\FM\09FEN1.SGM
09FEN1
]]>Agencies
[Federal Register Volume 71, Number 27 (Thursday, February 9, 2006)]
[Notices]
[Page 6777]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-1199]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Statement of Organization, Functions, and Delegations of
Authority
Part C (Centers for Disease Control and Prevention) of the
Statement of Organization, Functions, and Delegations of Authority of
the Department of Health and Human Services (45 FR 67772-76, dated
October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as
amended most recently at 70 FR 72842-72843, dated December 7, 2005) is
amended to reflect the title change for the Division of Injury and
Disability Outcomes, National Center for Injury Prevention and Control,
Centers for Disease Control and Prevention.
Section C-B, Organization and Functions, is hereby amended as
follows:
Delete in its entirety the title for the Division of Injury and
Disability Outcomes (CE6) and insert the Division of Injury Response
(CTCE).
Dated: January 27, 2006
William H. Gimson,
Chief Operating Officer, Centers for Disease Control and Prevention
(CDC).
[FR Doc. 06-1199 Filed 2-8-06; 8:45 am]
BILLING CODE 4160-18--M
